A Food and Drug Administration advisory committee voted Wednesday to recommend expanded labeling for Novo Nordisk's semaglutide (Ozempic/Wegovy) to include language acknowledging its potential role in reducing cognitive decline risk among adults with type 2 diabetes, following a review of emerging real-world and trial data. The 11-4 vote does not constitute formal approval of a new indication but signals growing regulatory openness to the cognition angle that has gained significant momentum in recent weeks.

The recommendation builds directly on a wave of research — highlighted in MedPage Today coverage on April 21 — that has unsettled prior assumptions about GLP-1 receptor agonists and brain health. Earlier studies had raised questions about whether the drugs offered neutral or mixed cognitive effects, but newer longitudinal data from large Medicare claims datasets appear to show a statistically significant reduction in dementia-related diagnostic codes among long-term GLP-1 users compared with matched controls on other diabetes therapies.

Novo Nordisk representatives presented updated post-market surveillance data to the panel, citing a cohort of over 180,000 patients tracked across a median of 4.2 years. The company stopped short of claiming a causal mechanism but argued the signal was strong enough to warrant updated physician guidance. Panelists who voted in favour cited the public health urgency of Alzheimer's disease, for which few preventive pharmacological tools currently exist.

Critics on the committee cautioned against premature label changes, arguing that randomised controlled trial evidence specifically powered for cognitive endpoints remains lacking. Dr. Maria Carrillo of the Alzheimer's Association, who presented as an invited expert, called the committee's vote 'a cautious but meaningful step,' urging the FDA to require Novo Nordisk to commit to a dedicated Phase III cognitive outcomes trial within 36 months as a condition of any label revision.

Shares of Novo Nordisk rose approximately 4% in after-hours trading following the vote, while rival Eli Lilly, whose tirzepatide competes in the GLP-1 space, was also expected to benefit from broader regulatory legitimisation of the drug class's neurological profile. Analysts at Morgan Stanley estimated that a formal cognitive indication, if eventually granted, could add between $6 billion and $9 billion to the global GLP-1 market by 2030, reshaping how neurologists and endocrinologists collaborate on high-risk patient management.